p53 Gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 385-394

  Temam, Stéphane ^a   Flahault, Antoine ^a   Périé, Sophie ^a   Monceaux, Guy ^a   Coulet, Florence ^a   Callard, Patrice ^a   Bernaudin, Jean François ^a   St Guily, Jean Lacau ^a   Fouret, Pierre ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PROTEIN P53;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC RISK; HEAD CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NECK CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0033969549     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.385     Document Type: Article

References (52)

1. Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7:15-29, 1996
2. Jacobs C, Goffinet DR, Goffinet L, et al: Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer: A report from the Northern California Oncology Group. Cancer 60:1178-1183, 1987
3. Karp DD, Vaughan CW, Carter R, et al: Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer: A long-term follow-up report. Am J Clin Oncol 14:273-279, 1991
4. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
5. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
6. Kies MS, Gordon LI, Hauck WW, et al: Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Otolaryngol Head Neck Surg 93:199-205, 1985
7. Forastiere AA: Randomized trials of induction chemotherapy: A critical review. Hematol Oncol Clin North Am 5:725-736, 1991
8. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
9. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
10. Brasnu D, Laccourreye O, Chabardes E, et al: Conservative surgery of the larynx as an alternative to total laryngectomy after neoadjuvant chemotherapy: Initial results. Ann Otolaryngol Chir Cervicofac 110:129-133, 1993
11. Bailet JW, Sercarz JA, Abemayor E, et al: The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 105:135-139, 1995
12. Sassler AM, Esclamado RM, Wolf GT: Surgery after organ preservation therapy: Analysis of wound complications. Arch Otolaryngol Head Neck Surg 121:162-165, 1995
13. Wolf GT, Makuch RW, Baker SR: Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The Head and Neck Contracts Program. Cancer 54:2869-2877, 1984
14. Spaulding MB, Fischer SG, Wolf GT: Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma: The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 12:1592-1599, 1994
15. Johnston PG, Mick R, Recant W, et al: Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89:308-313, 1997
16. Cheradame S, Etienne MC, Formento P, et al: Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients. J Clin Oncol 15:2604-2610, 1997
17. Reynolds T: Research on drug resistance unearths many molecules, many mechanisms. J Natl Cancer Inst 90:1120-1122, 1998
18. Evan G, Littlewood T: A matter of life and cell death. Science 281:1317-1322, 1998
19. de Stanchina E, McCurrach ME, Zindy F, et al: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12:2434-2442, 1998
20. Zindy F, Eischen CM, Randle DH, et al: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433, 1998
21. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
22. Liu TJ, el-Naggar AK, McDonnell TJ, et al: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122, 1995
23. Pirollo KF, Hao Z, Rait A, et al: p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14:1735-1746, 1997
24. Clayman GL, el-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998
25. Koch WM, Brennan JA, Zahurak M, et al: p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1580-1586, 1996
26. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7-18, 1998
27. Scheffner M, Huibregtse JM, Howley PM: Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A 91:8797-8801, 1994
28. Pfister DG, Harrison LB, Strong EW, et al: Organ-function preservation in advanced oropharynx cancer: Results with induction chemotherapy and radiation. J Clin Oncol 13:671-680, 1995
29. Hsu IC, Metcalf RA, Sun T, et al: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428, 1991
30. Lazarus P, Garewal HS, Sciubba J, et al: A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users. Int J Cancer 60:458-463, 1995
31. Cariello NF, Douglas GR, Gorelick NJ, et al: Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic Acids Res 26:200-202, 1998
32. Resnick RM, Cornelissen MT, Wright DK, et al: Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 82:1477-1484, 1990
33. Anwar K, Nakakuki K, Imai H, et al: Over-expression of p53 protein in human laryngeal carcinoma. Int J Cancer 53:952-956, 1993
34. Fouret P, Dabit D, Sibony M, et al: Expression of p53 protein related to the presence of human papillomavirus infection in precancer lesions of the larynx. Am J Pathol 146:599-604, 1995
35. Beahrs OH, Henson DE, Hutter RVP, et al (eds): American Joint Commitee on Staging: Manual for Staging of Cancer. Philadelphia, PA, Lippincott, 1992
36. Cho Y. Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994
37. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993
38. Lee NK, Ye YW, Chen J, et al: p53, retinoblastoma, and human papillomavirus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 119:1125-1131, 1993
39. Erber R, Conradt C, Homann N, et al: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679, 1998
40. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
41. Brennan JA, Boyle JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332:712-717, 1995
42. Melhem MF, Law JC, el-Ashmawy L, et al: Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 146:1170-1177, 1995
43. Wang YC, Chen CY, Chen SK, et al: High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 58:328-333, 1998
44. Midgley CA, Lane DP: p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189, 1997
45. Portugal LG, Goldenberg JD, Wenig BL, et al: Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 123:1230-1234, 1997
46. Ory K, Legros Y, Auguin C, et al: Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504, 1994
47. Forastiere AA, Shank D, Neuberg D, et al: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270-2274, 1998
48. Kies MS, Haraf DJ, Athanasiadis I, et al: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: Improved disease control and survival. J Clin Oncol 16:2715-2721, 1998
49. Casey G, Lopez ME, Ramos JC, et al: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981, 1996
50. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: Absence of correlation with clinical outcome-Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995
51. Hartmann A, Blaszyk H, Kovach JS, et al: The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13:27-33, 1997
52. Barnard R, Futo V, Pecheniuk N, et al: PCR bias toward the wild-type k-ras and p53 sequences: Implications for PCR detection of mutations and cancer diagnosis. Biotechniques 25:684-691, 1998